Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18804633 | 0.84 | KMT2A (0.39) | KMT2ACYP19A1PTK2PTK2BCLK2 | |
| SCHEMBL20246840 | 0.84 | KMT2A (0.35) | KMT2ACYP19A1PTK2PTK2BCLK2 | |
| SCHEMBL17187943 | 0.82 | KMT2A (0.39) | KMT2ACYP19A1PTK2PTK2BCLK2 | |
| SCHEMBL17196823 | 0.78 | KMT2A (0.37) | KMT2APTK2PTK2BCLK2AURKB | |
| SCHEMBL16822070 | 0.77 | P2RX7 (0.34) | — | |
| SCHEMBL17187948 | 0.75 | PTK2 (0.41) | KMT2APTK2SMN1; SMN2TYK2ALDH1A1 | |
| SCHEMBL17187964 | 0.74 | KMT2A (0.39) | KMT2APTK2CLK2AURKBCLK4 | |
| SCHEMBL17187868 | 0.74 | KMT2A (0.39) | KMT2APTK2PTK2BSMN1; SMN2TYK2 | |
| SCHEMBL28113687 | 0.71 | NPC1 (0.32) | PTK2PTK2BCLK2AURKBCLK4 | |
| SCHEMBL4679010 | 0.70 | IDO1 (0.56) | KMT2ANR3C1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023590-B2 | Substituted pyridine compounds having herbicidal activity | BASF SE (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10023590-B2 | Substituted pyridine compounds having herbicidal activity | BASF SE (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10023590-B2 | Substituted pyridine compounds having herbicidal activity | BASF SE (DE) | 2018-07-17 | — | — | US | disclosed |
| EP-3131906-B1 | SUBSTITUTED PYRIDINE COMPOUNDS HAVING HERBICIDAL ACTIVITY | BASF SE (DE) | 2018-06-13 | — | — | EP | disclosed |
| US-20170121343-A1 | Substituted Pyridine Compounds Having Herbicidal Activity | BASF SE (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121343-A1 | Substituted Pyridine Compounds Having Herbicidal Activity | BASF SE (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121343-A1 | Substituted Pyridine Compounds Having Herbicidal Activity | BASF SE (DE) | 2017-05-04 | — | — | US | disclosed |
| WO-2015158565-A1 | SUBSTITUTED PYRIDINE COMPOUNDS HAVING HERBICIDAL ACTIVITY | BASF SE (DE) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023590-B2 | Substituted pyridine compounds having herbicidal activity | DDT, PNPO, CYP4X1 | KMT2A 1337/4885CYP19A1 252/4885PTK2 4346/4885 |
| US-20170121343-A1 | Substituted Pyridine Compounds Having Herbicidal Activity | DDT, PNPO, CYP4X1 | KMT2A 1337/4885CYP19A1 252/4885PTK2 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.